CNRS, INSERM, CRCM, APHM, Multidisciplinary Oncology & Therapeutic Innovations Department, Aix Marseille University, Marseille, France.
Gustave Roussy Cancer Campus, Villejuif, France.
Curr Oncol Rep. 2020 Aug 15;22(11):107. doi: 10.1007/s11912-020-00970-3.
Lung cancer is still the first cause of cancer-related deaths worldwide. The development of immune checkpoint inhibitors (ICI) has drastically changed the prognosis of some patients, but the rate of long responders does not exceed 20%. Moreover, ICIs are not adverse events-free and remain expensive. Therefore, predictive biomarkers of long-term benefit to ICI are required.
The two main fields being evaluated currently are PD-L1 expression and tumor mutational burden (TMB). The first one is the only one used in routine practice, and the second is being evaluated in phase 3 clinical trials. In addition, other biomarkers are being assessed as complex signatures, tumor-infiltrated lymphocytes, T cell receptor repertoire, or molecular profiling. The aim of this review is to summarize the current validated or promising biomarkers in lung cancer which could help to better select patients who will respond to ICI.
肺癌仍是全球癌症相关死亡的首要原因。免疫检查点抑制剂（ICI）的发展极大地改变了一些患者的预后，但长期应答者的比例不超过 20%。此外，ICI 并非无不良反应且价格昂贵。因此，需要预测对 ICI 有长期获益的生物标志物。
目前正在评估的两个主要领域是 PD-L1 表达和肿瘤突变负担（TMB）。前者是唯一在常规实践中使用的，后者正在进行 3 期临床试验评估。此外，还在评估其他生物标志物，如复杂特征、肿瘤浸润淋巴细胞、T 细胞受体库或分子谱。本文综述的目的是总结目前在肺癌中经过验证或有前景的生物标志物，这些标志物可能有助于更好地选择对 ICI 有反应的患者。
